BETHLEHEM, PA, United States
BETHLEHEM, PA, United States

Time filter

Source Type

News Article | May 16, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 16, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS Global Healthcare Conference in New York, New York.  The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on May 23, 2017, at approximately 8:30 AM Eastern Time (5:30 AM Pacific Time).  Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com, and clicking on the Investor Info link.  A replay of the webcast will be available on OraSure Technologies’ web site for seven days.  Alternatively, you can access the live webcast of the presentation via the following link:  https://cc.talkpoint.com/ubsx001/052217a_as/?entity=37_J1YMCU8. OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.


News Article | May 16, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 16, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS Global Healthcare Conference in New York, New York.  The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on May 23, 2017, at approximately 8:30 AM Eastern Time (5:30 AM Pacific Time).  Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com, and clicking on the Investor Info link.  A replay of the webcast will be available on OraSure Technologies’ web site for seven days.  Alternatively, you can access the live webcast of the presentation via the following link:  https://cc.talkpoint.com/ubsx001/052217a_as/?entity=37_J1YMCU8. OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.


News Article | May 16, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 16, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS Global Healthcare Conference in New York, New York.  The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on May 23, 2017, at approximately 8:30 AM Eastern Time (5:30 AM Pacific Time).  Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com, and clicking on the Investor Info link.  A replay of the webcast will be available on OraSure Technologies’ web site for seven days.  Alternatively, you can access the live webcast of the presentation via the following link:  https://cc.talkpoint.com/ubsx001/052217a_as/?entity=37_J1YMCU8. OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.


This report, Top 50 Companies in Point-of-Care Diagnostic Testing, profiles the following companies based on their size, product range, innovative capacity and influence in the market: Diagnostic tests performed outside the central laboratory or decentralized testing is generally known as point-of-care (POC).   The market is large and companies of various sizes are involved in the development and/or marketing of POC testing. The market is considered evolving with growth opportunity. Developing and developed markets alike have room to grow due to an aging population worldwide. Over the years, the increasing introduction of transportable, portable, and handheld instruments has resulted in the migration of POC testing from the hospital environment to a range of medical environments including the workplace, home, disaster care and most recently, convenience clinics. In addition to profiles of these companies and recent revenue performance where financial information is available, the report provides market sizing and share for the entire POC test market. It also provides market data, including: - Alere - Abbott, Danaher Cepheid and Other Industry Developments - Size and Growth of the Point-of-Care Diagnostics Market, 2016-2021 - Market by Test Segment (Glucose, Pregnancy, FOB, Infectious Disease, Coagulation, Other) - Market by Self-Testing or Professional Testing - Market Share by Vendor - Company Profiling and Revenue Performance - Trends in the Industry Key Topics Covered: 1: Executive Summary - Introduction - Scope and Methodology - Size and Growth Of The Point-Of-Care Market - Trend - Alere and Abbott Merger - Trend - "Star Trek" POC Devices - Trend - Danaher Buys Cepheid - Trend - Retail Clinics - Companies In The POC Market 2: Top 50 Point Of Care Diagnostic Companies - Corporate Profiles - Abaxis, Inc. - Abbott Laboratories - Accriva Diagnostics - Accubiotech Co, Ltd. - Acon Laboratories, Inc - Alere Inc - Arkray - Atlas Genetics Ltd. - Atlas Link Biotech Co., Ltd. - Beckman Coulter, Inc. - Church & Dwight Co. Inc - Danaher Corporation - Dexcom, Inc - Dragerwerk Ag & Co.  - Eiken Chemical Co Ltd. - EKF Diagnostics - Enigma Diagnostics, Ltd. - Enterix, Inc - Exact Sciences - Helena Laboratories - Menarini Diagnostics - Meridian Bioscience, Inc - Micronics, Inc - Nova Biomedical, Corp. - Opko Health, Inc - Orasure Technologies, Inc. - Ortho Clinical Diagnostics - Polymer Technologies, Inc (Pts Diagnostics) - Roche Diagnostic Corporation - Samsung Healthcare - Sekisui Diagnostics - Siemens Healthineers - Sysmex Corporation - Trinity Biotech  - Veredus Laboratories  Ltd 3: POC Testing Market Share And Market Analysis For more information about this report visit http://www.researchandmarkets.com/research/9r93k4/top_50_companies Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/top-50-companies-in-point-of-care-diagnostic-testing-2017-with-size-and-growth-of-the-point-of-care-diagnostics-market-2016-2021---research-and-markets-300462487.html


Patent
Orasure Technologies, Inc. | Date: 2012-07-16

A sample collection kit includes a sample collector, a polycarbonate container, and a preservative solution. The sample collector includes an absorbent pad with a collecting element that receives a sample of oral fluid. The absorbent pad also includes an interior portion that extends into a handle. The handle includes an upper casing and a lower casing. The collecting element can be treated with a surfactant to optimize recovery of analytes from the oral sample and/or their absorbance onto the absorbent pad. A polycarbonate container receives the absorbent pad or the sample collector and stores it for testing of analytes. A dextran sulfate preservative solution is included in the polycarbonate container that inhibits enzymatic activity on a collected sample.


Patent
Orasure Technologies, Inc. | Date: 2011-11-21

A method and a device for collection and assay of oral fluids are disclosed. The method places an assay device into an oral cavity, removes the device, and determines the presence or absence of an analyte. The assay device comprises an assay portion housing a lateral flow assay strip, a neck portion extending from the assay portion and forming a channel for fluid delivery to the assay strip; a collection strip in fluid communication with the lateral flow assay strip; and a blocking strip coupled between and in flow communication with the lateral flow assay strip and the collection strip. The channel is defined by a narrow part proximal to the assay portion and a part which receives oral fluid and has a substantially wider channel width. The collection strip has a first portion disposed within the channel and a second portion protruding outwardly from the neck opening.


Patent
Orasure Technologies, Inc. | Date: 2011-01-31

A sample collector and test device is disclosed. The sample collector and test device may be used together as a diagnostic tool for collecting and assay of analytes contained in a sample. A sample collector is also disclosed which may be used with existing sample containers and or test devices. The sample collector may indicate sample adequacy when a sufficient volume of sample has been collected for assay and may also include a sample retaining feature which retains a portion of expressed sample for confirmatory testing, if desirable. The sample collector may also include a mechanism for expressing sample in a sample collector and/or test device. A test device is also disclosed for retaining and assay of an expressed sample. The disclosed test device may be used with existing sample collectors. In a preferred embodiment, test device is used with a preferred sample collector. Test device may include a locking feature for locking a sample retained on a sample collector or test device may be used to receive expressed sample collected from a syringe or another suitable sample delivery device.


Patent
Orasure Technologies, Inc. | Date: 2015-02-18

A cryo-surgical system may comprise a container containing a refrigerant, a delivery tube having a first end configured to be in flow communication with the container and a second end opposite the first end. The system may further include a plurality of flexible finger portions disposed proximate a second end of the delivery tube opposite the first end, an applicator bud having a body portion disposed within the plurality of flexible finger portions and a contact surface extending from the plurality of flexible finger portions. An adjustment ring may be disposed along the delivery tube adjacent to the plurality of flexible finger portions. The contact surface of the bud may be changeable by adjustment of the adjustment ring.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 145.91K | Year: 2012

DESCRIPTION (provided by applicant): The objective of this research application is the development of a simple, highly portable test system for rapid screening for human immunodeficiency virus (HIV) and hepatitis at the point of care (POC). This test system will be capable of identifying patients infected by HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) in a small drop of blood obtained by finger stick. This will allow the use of this test syste in settings such as physician offices, public health testing clinics, community outreach centers and mobile testing facilities. It is the intention to obtain regulatory approvals in the US, such tat this system can be used outside of traditional laboratory settings by individuals with minimal training. This will enable maximum access to populations at greatest risk for HIV and hepatitis. It is expected that by enabling increased testing of high risk populations, a higher proportion of infected individuals will be diagnosed and gain earlier access to appropriate medical treatment. The test system will consist of test cartridges specific for each disease state and a simple-to-use instrument providing objective results to the user. Use of manual, rapid tests has previously been shown to be effective in increasing diagnosis of HIV. Currently, approximately 25% of HIV infection and more than half of the cases of HCV and HBV infection are undiagnosed. This reservoir of undiagnosed infection represents a growing burden of mortality and morbidity and also contributes to greater transmission rates within the population. Improved therapeutic outcomes in infected individuals who are treated earlier in the course of disease are now well documented. Improved the rapid tests for treatment of HCV were recently approved inthe US and reduction of future morbidity and mortality will be highly dependent on expanded testing and diagnoses. Additionally, early treatment of HIV infected individuals has been shown to greatly reduce the risk of disease transmission. Increased testing and treatment of individuals infected with these blood borne viruses will significantly improve health outcomes in infected individuals and reduce transmission through reduction of community viral burden. PUBLIC HEALTH RELEVANCE: The purpose ofthis project is to develop a new and proprietary system that can detect the presence of infection by HIV, hepatitis B or hepatitis C from a small drop of finger-stick blood. This will expand testing opportunities, increase disease diagnoses and enable moreindividuals to become more aware of their status and thus receive earlier intervention in the course of disease. This will result in improved health care outcomes; reduced disease transmission, as well as reducing overall medical costs.


Patent
Orasure Technologies, Inc. | Date: 2014-12-05

A method of preparing a cryo-surgical system for treatment includes accessing a container containing a refrigerant, a delivery tube having a first end configured to be in flow communication with the container and a second end opposite the first end. The system further includes a plurality of flexible finger portions disposed proximate the second end of the delivery tube opposite the first end. A porous applicator bud is disposed proximate the second end of the delivery tube. The porous applicator bud includes a body portion disposed between the plurality of flexible finger portions and a contact surface extending from the plurality of flexible finger portions. An adjustment ring disposed along the delivery tube adjacent to the plurality of flexible finger portions can be used to adjust the size of the contact surface of the porous applicator bud.

Loading Orasure Technologies, Inc. collaborators
Loading Orasure Technologies, Inc. collaborators